ReviewWorld journal of gastroenterology2018
Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells.
Review in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Platelet‑circulating tumor cell crosstalk: A pivotal target in cancer diagnosis and therapy (Review).Oncology reports · 2026Review
- Bibliometric-driven research on chemoresistance in breast cancer: knowledge mapping, hotspot evolution, and emerging insights (1994-2024).Discover oncology · 2025Article
- Article
- Integrin β5, a noninvasive diagnostic biomarker, is associated with unfavorable prognosis and immunotherapy efficacy in gastric cancer.BMC gastroenterology · 2024Article
- MUC16 as a serum-based prognostic indicator of prometastatic gastric cancer.Scientific reports · 2024Article
- Potential diagnostic, prognostic, and predictive biomarkers of gastric cancer.Health science reports · 2024Article
- Landscape of Innovative Methods for Early Diagnosis of Gastric Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2023Review
- Circulating Tumor DNA in Gastric Adenocarcinoma: Future Clinical Applications and Perspectives.International journal of molecular sciences · 2023Review
- Tumor budding in gastric cancer.World journal of gastrointestinal surgery · 2023Review
- Clinical application and detection techniques of liquid biopsy in gastric cancer.Molecular cancer · 2023Review
- Biomarkers of gastric cancer: current advancement.Heliyon · 2022Review
- Molecular and Circulating Biomarkers of Gastric Cancer.International journal of molecular sciences · 2022Review
- Article
- Nomograms predicting prognosis of patients with pathological stages T1N2-3 and T3N0 gastric cancer.World journal of gastrointestinal surgery · 2022Article
- Bacteria derived extracellular vesicles in the pathogenesis and treatment of gastrointestinal tumours.Frontiers in oncology · 2022Review
- Clinical Utility of Circulating Tumor Cells in Patients With Esophageal Cancer.Frontiers in oncology · 2022Article
- Immune-Related Nine-MicroRNA Signature for Predicting the Prognosis of Gastric Cancer.Frontiers in genetics · 2021Article
- Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report.OncoTargets and therapy · 2021Article
- Article
- Long intergenic non-protein-coding RNA 01446 facilitates the proliferation and metastasis of gastric cancer cells through interacting with the histone lysine-specific demethylase LSD1.Cell death & disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC), with its high incidence and mortality rates, is a highly fatal cancer that is common in East Asia particularly in China. Its recurrence and metastasis are the main causes of its poor prognosis. Circulating tumor cells (CTCs) or other blood biomarkers that are released into the circulating blood stream by tumors are thought to play a crucial role in the recurrence and metastasis of gastric cancer. Therefore, the detection of CTCs and other blood biomarkers has an important clinical significance; in fact, they can help predict the prognosis, assess the staging, monitor the therapeutic effects and determine the drug susceptibility. Recent research has identified many blood biomarkers in GC, such as various serum proteins, autoantibodies against tumor associated antigens, and cell-free DNAs. The analysis of CTCs and circulating cell-free tumor DNA (ctDNA) in the peripheral blood of patients with gastric cancer is called as liquid biopsy. These blood biomarkers provide the disease status for individuals and have clinical meaning. In this review, we focus on the recent scientific advances regarding CTCs and other blood biomarkers, and discuss their origins and clinical meaning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.